Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE: ELEVIDYS in Post-Marketing Setting for Duchenne Muscular Dystrophy
NCT07542314Phase 4Recruiting
- Sponsor
- Sarepta Therapeutics
- Start
- Oct 2026
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
A Phase 4 trial of delandistrogene moxeparvovec in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Started Oct 2026; status: recruiting.
02
Drugs
delandistrogene moxeparvovec
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07542314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07542314.